Heinzel Sebastian, Berg Daniela, Binder Sebastian, Ebersbach Georg, Hickstein Lennart, Herbst Heinz, Lorrain Michael, Wellach Ingmar, Maetzler Walter, Petersen Gudula, Schmedt Niklas, Volkmann Jens, Woitalla Dirk, Amelung Volker
Department of Neurology, Christian-Albrechts-University, Kiel, Germany.
Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
Front Neurol. 2018 Jun 29;9:500. doi: 10.3389/fneur.2018.00500. eCollection 2018.
Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases had at least one main hospital discharge diagnosis of PD, or one physician diagnosis confirmed by a subsequent or independent diagnosis or by PD medication in 2015. Prevalence of (co-)occurring diseases, mortality, and healthcare measures in PD cases and matched controls were compared. In 2015, 21,714 prevalent PD cases (standardized prevalence: 511.4/100,000 persons) and 3,541 incident PD cases (standardized incidence: 84.1/100,000 persons) were identified. Prevalence of several (co-)occurring diseases/complications, e.g., dementia (PD/controls: 39/13%), depression (45/22%), bladder dysfunction (46/22%), and diabetes (35/31%), as well as mortality (10.7/5.8%) differed between PD cases and controls. The annual healthcare utilization was increased in PD cases compared to controls, e.g., regarding mean ± SD physician contacts (15.2 ± 7.6/12.2 ± 7.3), hospitalizations (1.3 ± 1.8/0.7 ± 1.4), drug prescriptions (overall: 37.7 ± 24.2/21.7 ± 19.6; anti-PD medication: 7.4 ± 7.4/0.1 ± 0.7), assistive/therapeutic devices (47/30%), and therapeutic remedies (57/16%). The standardized prevalence and incidence of PD in Germany as well as mortality in PD may be substantially higher than reported previously. While frequently diagnosed with co-occurring diseases/complications, such as dementia, depression, bladder dysfunction and diabetes, the degree of healthcare utilization shows large variability between PD patients. These findings encourage a rethinking of the epidemiology and healthcare utilization in PD, at least in Germany. Longitudinal studies of insurance claims data should further investigate the individual and epidemiological progression and healthcare demands in PD.
帕金森病(PD)的流行病学特征、共病情况以及PD患者的医疗保健利用情况在很大程度上仍不明确。基于2015年德国370万法定医保参保人的理赔数据,确定了PD的患病率和发病率。PD病例在2015年至少有一次主要出院诊断为PD,或有一次经后续或独立诊断确认的医生诊断,或有PD药物治疗记录。比较了PD病例和匹配对照组中(共)发病情况、死亡率及医疗保健措施。2015年,共识别出21,714例PD现患病例(标准化患病率:511.4/10万人)和3,541例PD新发病例(标准化发病率:84.1/10万人)。PD病例和对照组在几种(共)发病疾病/并发症的患病率上存在差异,如痴呆(PD/对照组:39%/13%)、抑郁症(45%/22%)、膀胱功能障碍(46%/22%)和糖尿病(35%/31%),以及死亡率(10.7%/5.8%)。与对照组相比,PD病例的年度医疗保健利用率有所增加,例如,平均±标准差的医生诊疗次数(15.2±7.6/12.2±7.3)、住院次数(1.3±1.8/0.7±1.4)、药物处方(总体:37.7±24.2/21.7±19.6;抗PD药物:7.4±7.4/0.1±0.7)、辅助/治疗设备(47%/30%)和治疗手段(57%/16%)。德国PD的标准化患病率和发病率以及PD患者的死亡率可能远高于此前报道。虽然PD患者常被诊断伴有共病疾病/并发症,如痴呆、抑郁症、膀胱功能障碍和糖尿病,但PD患者的医疗保健利用程度差异很大。这些发现促使人们重新思考PD的流行病学和医疗保健利用情况,至少在德国是这样。对保险理赔数据的纵向研究应进一步调查PD的个体和流行病学进展以及医疗保健需求。